Data Integrity: US FDA Seeks Dismissal Of CRO Semler’s Lawsuit For Lost Business
Executive Summary
Contract research organization’s claims that agency improperly relied on a ‘suspect spreadsheet’ in taking actions that damaged its business are barred by sovereign immunity and exceptions to the Federal Tort Claims Act, FDA says; a federal judge in California will hear arguments on motions to dismiss Jan. 15.
You may also be interested in...
CRO Does Not Have Same Rights As Sponsor, Court Says In Tossing Semler Suit Against US FDA
Requiring re-do of Semler bioequivalence studies did not violate the CRO's due process rights, court finds; government has sovereign immunity from 'interference with economic advantage' claims.
US Federal Courts Can Operate Until Jan. 25; Patent Office Faces Eminent Closure Under Shutdown
Federal courts and USPTO will soon run out of funds that have allowed them to continue normal operations; pending ANDAs to get same filing date, which could lead to FDA legal challenges.
The Case Of The Suspect Spreadsheet: Semler Sues US FDA Over Data Integrity Concerns
India-based CRO alleges FDA 'annihilated' its business with announcement that sponsors must re-do bioequivalence and bioavailability studies; Semler asserts invalid or falsified study data were never submitted to the agency and FDA's conclusions rest upon a 'suspect spreadsheet' created by a 'rogue employee.'